15:34 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Daiichi's AML candidate leads to median OS of 6.2 months

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported additional data from the Phase III QuANTUM-R trial to treat relapsed or refractory acute myelogenous leukemia (AML) showing that oral quizartinib led to median overall survival (OS), the primary...
15:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Daiichi planning NDA for pexidartinib on Phase III TGCT data

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported data from 120 patients with symptomatic advanced tenosynovial giant cell tumors (TGCT) in the Phase III ENLIVEN trial showing that oral pexidartinib (PLX3397) led to an overall response...
19:09 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Astellas' AML candidate gilteritinib

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:00 , May 29, 2018 |  BC Extra  |  Company News

FDA reviewing Astellas' AML candidate

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an NDA for gilteritinib to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation....
19:02 , May 25, 2018 |  BC Week In Review  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...
23:05 , May 22, 2018 |  BC Extra  |  Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company Tuesday, including a restructuring of R&D and Japan operations. The pharma anticipates...
17:11 , May 11, 2018 |  BC Week In Review  |  Clinical News

Daiichi planning regulatory submissions for AML candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said quizartinib met the primary endpoint of improving overall survival (OS) vs. salvage chemotherapy in the Phase III QuANTUM-R trial to treat relapsed or refractory acute myelogenous leukemia (AML). The...
19:06 , May 8, 2018 |  BC Extra  |  Clinical News

Daiichi planning regulatory submissions for AML candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said quizartinib met the primary endpoint of improving overall survival (OS) vs. salvage chemotherapy in the Phase III QuANTUM-R trial to treat relapsed or refractory acute myelogenous leukemia. The company...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse studies suggest the small molecule FLT3 inhibitor BDT001 could help treat peripheral neuropathy. In one mouse model of nerve injury-induced and two mouse models of chemically-induced peripheral neuropathy, FLT3 knockout decreased mechanical...
19:51 , Mar 14, 2018 |  BC Extra  |  Preclinical News

FLT3 inhibitor reduces peripheral neuropathic pain

A study published in Nature Communications suggests that inhibiting FMS-like tyrosine kinase 3 (FLT3; CD135) with a small molecule inhibitor could help treat peripheral nerve pain. Current therapies to treat peripheral nerve pain, including off-label antidepressants...